BioXcel Therapeutics

-$0.63 (-2.93%) As of 3:06 PM UTC today

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell BTAI and other ETFs, options, and stocks.

About BTAI

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on drug development. The firm's two clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer.

CEO
Vimal D. Mehta
Employees
50
Headquarters
New Haven, Connecticut
Founded
2017

BTAI Key Statistics

Market cap
582.87M
Price-Earnings ratio
—
Dividend yield
—
Average volume
391.09K
High today
$21.22
Low today
$20.20
Open price
$21.22
Volume
35.05K
52 Week high
$67.74
52 Week low
$18.82

BTAI Earnings

-$1.11
-$0.74
-$0.37
$0.00
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Q4 FY21
Estimated
— per share
Actual
Expected Mar 10, Pre-Market
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure